Medicines
General information about medicines, as well as advice on safety information, medicines and pregnancy, and medicine shortages.
More information
- Medicines
- How we regulate medicines
- Australia's medicine labels are becoming clearer
- Tamper-evident packaging
- PI/CMI search facility
- Medicines Repurposing Program - Eligibility criteria and prioritisation considerations
Dispose of unwanted medicines
Health professionals
University student education materials
Latest alerts
- Orencia (abatacept) subcutaneous medicines shortages have resolvedShortage resolved
- Medicines containing Garcinia gummi-gutta (Garcinia cambogia) or hydroxycitric acid (HCA)We have become aware of an increasing number of cases of liver injury reported in scientific literature, by consumers who had taken products containing Garcinia gummi-gutta.
- New semaglutide product becomes availablePharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.
Latest articles
- New quality standards for MDMA and psilocybineTwo new quality standards, one for MDMA and another for psilocybine, have been published.
- Product Information safety updates - August 2024Information for health professionals about medicines with safety related updates to their product information.
Guidance changes are coming soonSome changes are rolling out soon to improve your experience using guidance on our website. We’re aiming to make our content clearer, more accessible and easier to navigate.
Events and webinars
Latest publications
- ACM meeting statement, Meeting 45, 6 and 7 June 2024Advisory Committee on Medicines meeting statement
- ACM meeting statement, Meeting 44, 4 and 5 April 2024Advisory Committee on Medicines meeting statement
- Cost Recovery Implementation Statement 2024-2025This Cost Recovery Implementation Statement (CRIS) 2024-2025 provides information on how we implement, and cost recover our regulatory activities.
Latest consultations
- Consultation: 2024-2025 Proposed changes to the Permissible Ingredients Determination – Low-negligible riskThe TGA is seeking feedback from interested parties on proposed changes to the requirements of ingredients used in listed (low-risk) medicines.
- Consultation: Therapeutic Goods Order No. 70C – Standards for Export Only MedicineThe TGA is seeking feedback from interested parties on the proposed changes to replace the sunsetting TGO 70C with a new instrument
- Consultation: Reforming Australia’s Therapeutic Goods Testing RegulationsHave your say on potential reforms to Part 5 of the Therapeutic Goods Regulations 1990.